Edmonton Symptom Assessment Scale and Clinical Characteristics Associated With Cannabinoid Use in Oncology Supportive Care Outpatients.
Adult
Aged
Aged, 80 and over
Ambulatory Care
/ statistics & numerical data
Cannabinoids
/ administration & dosage
Drug Utilization
/ statistics & numerical data
Female
Humans
Male
Medical Oncology
/ methods
Middle Aged
Neoplasms
/ epidemiology
Odds Ratio
Palliative Care
/ statistics & numerical data
Practice Patterns, Physicians'
Retrospective Studies
Young Adult
Journal
Journal of the National Comprehensive Cancer Network : JNCCN
ISSN: 1540-1413
Titre abrégé: J Natl Compr Canc Netw
Pays: United States
ID NLM: 101162515
Informations de publication
Date de publication:
01 09 2019
01 09 2019
Historique:
received:
15
10
2018
accepted:
26
03
2019
entrez:
6
9
2019
pubmed:
6
9
2019
medline:
18
8
2020
Statut:
ppublish
Résumé
Information about the frequency of cannabinoid use and the clinical characteristics of its users in oncology supportive care is limited. This study explored associations between cannabinoid use and cancer-related clinical characteristics in a cancer population. This retrospective review included 332 patients who had a urine drug test (UDT) for tetrahydrocannabinol (THC) together with completion of an Edmonton Symptom Assessment Scale (ESAS) and cannabinoid history questionnaire on the same day that urine was obtained during 1 year in the supportive care clinic. The frequency of positive results for THC in a UDT was 22.9% (n=76). Significant statistical differences were seen between THC-positive and THC-negative patients for age (median of 52 [lower quartile, 44; upper quartile, 56] vs 58 [48; 67] years; P<.001), male sex (53.9% vs 39.5%; P=.034), and past or current cannabinoid use (65.8% vs 26.2%; P<.001). Statistical significance was observed in ESAS items between the THC-positive and THC-negative groups for pain (7 [lower quartile, 5; upper quartile; 8] vs 5 [3; 7]; P=.001), nausea (1 [0; 3] vs 0 [0; 3]; P=.049), appetite (4 [2; 7] vs 3 [0; 5.75]; P=.015), overall well-being (5.5 [4; 7] vs 5 [3; 6]; P=.002), spiritual well-being (5 [2; 6] vs 3 [1; 3]; P=.015), insomnia (7 [5; 9] vs 4 [2; 7]; P<.001), and total ESAS (52 [34; 66] vs 44 [29; 54]; P=.001). Among patients who reported current or past cannabinoid use, THC-positive patients had higher total scores and scores for pain, appetite, overall well-being, spiritual well-being, and insomnia than THC-negative patients. Patients with cancer receiving outpatient supportive care who had positive UDT results for THC had higher symptom severity scores for pain, nausea, appetite, overall and spiritual well-being, and insomnia compared with their THC-negative counterparts. These results highlight potential opportunities to improve palliative care.
Sections du résumé
BACKGROUND
Information about the frequency of cannabinoid use and the clinical characteristics of its users in oncology supportive care is limited. This study explored associations between cannabinoid use and cancer-related clinical characteristics in a cancer population.
PATIENTS AND METHODS
This retrospective review included 332 patients who had a urine drug test (UDT) for tetrahydrocannabinol (THC) together with completion of an Edmonton Symptom Assessment Scale (ESAS) and cannabinoid history questionnaire on the same day that urine was obtained during 1 year in the supportive care clinic.
RESULTS
The frequency of positive results for THC in a UDT was 22.9% (n=76). Significant statistical differences were seen between THC-positive and THC-negative patients for age (median of 52 [lower quartile, 44; upper quartile, 56] vs 58 [48; 67] years; P<.001), male sex (53.9% vs 39.5%; P=.034), and past or current cannabinoid use (65.8% vs 26.2%; P<.001). Statistical significance was observed in ESAS items between the THC-positive and THC-negative groups for pain (7 [lower quartile, 5; upper quartile; 8] vs 5 [3; 7]; P=.001), nausea (1 [0; 3] vs 0 [0; 3]; P=.049), appetite (4 [2; 7] vs 3 [0; 5.75]; P=.015), overall well-being (5.5 [4; 7] vs 5 [3; 6]; P=.002), spiritual well-being (5 [2; 6] vs 3 [1; 3]; P=.015), insomnia (7 [5; 9] vs 4 [2; 7]; P<.001), and total ESAS (52 [34; 66] vs 44 [29; 54]; P=.001). Among patients who reported current or past cannabinoid use, THC-positive patients had higher total scores and scores for pain, appetite, overall well-being, spiritual well-being, and insomnia than THC-negative patients.
CONCLUSIONS
Patients with cancer receiving outpatient supportive care who had positive UDT results for THC had higher symptom severity scores for pain, nausea, appetite, overall and spiritual well-being, and insomnia compared with their THC-negative counterparts. These results highlight potential opportunities to improve palliative care.
Identifiants
pubmed: 31487688
doi: 10.6004/jnccn.2019.7301
pii: jnccn18269
pmc: PMC7771367
mid: NIHMS1653246
doi:
pii:
Substances chimiques
Cannabinoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1059-1064Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Références
Drug Alcohol Depend. 2014 Nov 1;144:12-41
pubmed: 25220897
J Clin Oncol. 2018 Jul 1;36(19):1957-1962
pubmed: 29746226
J Natl Compr Canc Netw. 2016 Jul;14(7):915-22
pubmed: 27407130
Clin J Oncol Nurs. 2013 Aug 1;17(4):360-2
pubmed: 23899972
CA Cancer J Clin. 2015 Mar;65(2):109-22
pubmed: 25503438
J Clin Oncol. 2018 Apr 10;36(11):1103-1111
pubmed: 29494259
Curr Oncol. 2018 Jun;25(3):219-225
pubmed: 29962840
Prostaglandins Other Lipid Mediat. 2009 Sep;89(3-4):105-11
pubmed: 19615459
Br J Clin Pharmacol. 2018 Nov;84(11):2477-2482
pubmed: 30001569
J Palliat Care. 1991 Summer;7(2):6-9
pubmed: 1714502
Curr Clin Pharmacol. 2016;11(2):110-7
pubmed: 27086601
Curr Oncol Rep. 2019 Feb 1;21(1):10
pubmed: 30707319
Res Social Adm Pharm. 2016 Jul-Aug;12(4):638-54
pubmed: 26443472
Acta Physiol (Oxf). 2012 Feb;204(2):255-66
pubmed: 21726418
Annu Rev Clin Psychol. 2017 May 8;13:397-419
pubmed: 28482686
Can Fam Physician. 2018 Feb;64(2):e78-e94
pubmed: 29449262
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
J Am Board Fam Med. 2017 Nov-Dec;30(6):795-805
pubmed: 29180554
J Pain Symptom Manage. 2017 Mar;53(3):630-643
pubmed: 28042071
Mol Neurobiol. 2007 Aug;36(1):92-101
pubmed: 17952654
Int J Drug Policy. 2014 Jul;25(4):691-9
pubmed: 24947993
Anal Bioanal Chem. 2010 Apr;396(7):2493-502
pubmed: 20112012
Front Mol Neurosci. 2019 Jan 15;11:487
pubmed: 30697147
Cancer Med. 2018 Mar;7(3):765-775
pubmed: 29473338
Prev Med. 2017 Nov;104:13-23
pubmed: 28705601
J Cachexia Sarcopenia Muscle. 2018 Apr;9(2):220-234
pubmed: 29400010
Expert Opin Investig Drugs. 2014 Aug;23(8):1123-40
pubmed: 24836296
Cancer. 2017 Nov 15;123(22):4488-4497
pubmed: 28944449
Subst Abuse. 2018 May 17;12:1178221818774264
pubmed: 29795983